European Commission approves Dupixent for children aged 2–11 with chronic spontaneous urticaria
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced on April 13, 2026, that the European Commission, has expanded the marketing authorization for Dupixent (dupilumab) to include children aged 2 to 11 years with moderate-to-severe chronic spontaneous urticaria (CSU).







-640x366.webp&w=3840&q=75)


